CClinicalTrials.gg
Not yet recruitingNCT07512466Updated Apr 6, 2026

Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations

An interventional study of endoscopic approch in Nasal Cavity and Paranasal Sinus Cancer, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Year to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
1 Year to 80 Years
Sex
All
01

Study summary

Research outcome measures:

  1. Primary (main):

    To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas

  2. Secondary (subsidiary):

    1. Assess postoperative improvement in Quality of Life
    2. Quantify intraoperative blood loss and surgical duration
    3. Document the incidence of complications (CSF leak, nerve palsy, vascular injury)
Read the detailed description

Sinonasal tumors are a heterogeneous group of neoplasms arising from the nasal cavity and paranasal sinuses, representing a rare subset of head and neck tumors. Tumors arising from the sinonasal cavity can be subdivided into benign and malignant characters .Sinonasal malignancy are rare, representing \<1% of all malignancies and \<5% of head and neck cancers.Benign sinonasal tumors are more common than malignant lesions and include inverted papilloma, hemangioma, osteoma, juvenile nasopharyngeal angiofibroma, and various fibrous and glandular neoplasms.(1)The sinonasal cavity includes the epithelial, mesenchymal, salivary gland, cartilaginous and osseous proponents, and as such, it may lead to various original malignancies including the squamous cell carcinoma (most common) and the others (adenocarcinoma, adenoid cystic carcinoma, sarcoma, olfactory neuroblastoma,).(2) Surgical resection is often the first step of the therapeutic strategy in treatment of sinonasal tumors, possibly combined with adjuvant therapies .Tumors at pterygopalatine and infratemporal fossae,sphenoid and maxillary sinus poses challenges to surgeons for their deep location and intimate relationship with highly functional neurovascular and osteo-muscular structures .(3)Tumors in these challenging regions were managed via invasive open surgical resection ,these interventions are frequently morbid, resulting in profound neurological and functional sequelae that adversely impact the patient's clinical outcomes.(4) Endoscopic endonasal surgery become a standard approach in the management of many benign and selected malignant sinonasal tumors .It is as a minimally invasive surgical alternative, facilitating access to difficult locations with preserving the osteo-ligamental and muscular structures with no visible scars, optimal cosmetic outcome, and consequently limited risk of permanent neurological or functional deficits.(5)

02

Conditions studied

  • Nasal Cavity and Paranasal Sinus Cancer
03

In context

Paranasal Sinus Neoplasms

55 studies on the registry are indexed under Paranasal Sinus Neoplasms; 6 are open to participants now.

This study's planned enrollment of 25 is below the median of 32 across 48 interventional studies indexed under Paranasal Sinus Neoplasms.

Browse Paranasal Sinus Neoplasms studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

-Patients with sinonasal and nasopharyngeal tumors

Exclusion criteria

Exclusion Criteria:

  • Extensive lesions required open approach ex (intraconal extension need orbital exenteration).
  • Absolute contraindications to general anaesthesia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    endoscopic resection of sinonasal tumors

    Procedure: endoscopic approch

Interventions

  • Procedureendoscopic approch

    mangment of endoscopic approch in sinonasal tumors excision

06

What researchers measure

Primary outcomes

  1. Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations

    To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas

    Time frame: 4 years

  2. percentage of complete resection post operative

    complete resection of tumer by endoscopic approch

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07512466
Lead sponsor
Assiut University
Responsible party
Aya abdelnasser hassani (Dr, Assiut University) — Principal investigator
First posted
Apr 6, 2026
Start date
Apr 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion